[
  {
    "Company": "Acadia",
    "COUNTRY": "USA",
    "Public/Private": "Public",
    "MarketCap": "3.25 billion",
    "RPDD Month": "3",
    "RPDD Year": "2020",
    "Current Development Stage": "PRV Awarded",
    "PRV Year": "2023",
    "PRV Month": "3",
    "Date": "10",
    "TherapeuticArea1": "Hepatology",
    "TherapeuticArea2": "",
    "Indication": "Rett Syndrome",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Candidate": "DAYBUE",
    "Active Ingredient": "trofinetide",
    "Class1": "Analogs & derivatives",
    "Class2": "",
    "Class3": "",
    "MOA": "Glycine-proline-glutamate analog",
    "Redeemed": "",
    "Purchased": "Y",
    "Purchaser": "Undisclosed",
    "Sale Price (USD Millions)": "150",
    "Purchase Month": "11",
    "Purchase Date": "6",
    "Purchase Year": "2024",
    "Acquisition": "N",
    "Acquirer": "NA",
    "Acquisition Price": "NA",
    "Acq month": "NA",
    "Acq date": "NA",
    "Acq year": "NA",
    "Acq notes": ""
  },
  {
    "Company": "Albireo AB",
    "COUNTRY": "Sweden",
    "Public/Private": "Public",
    "MarketCap": "1.1 billion",
    "RPDD Month": "6",
    "RPDD Year": "2018",
    "Current Development Stage": "PRV Awarded",
    "PRV Year": "2022",
    "PRV Month": "10",
    "Date": "7",
    "TherapeuticArea1": "Hepatology",
    "TherapeuticArea2": "",
    "Indication": "progressive familial intrahepatic cholestasis",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Candidate": "BYLVAY",
    "Active Ingredient": "odevixibat",
    "Class1": "Enzyme inhibitor",
    "Class2": "",
    "Class3": "",
    "MOA": "Ileal bile acid transporter (IBAT) inhibitor",
    "Redeemed": "",
    "Purchased": "Y",
    "Purchaser": "Undisclosed",
    "Sale Price (USD Millions)": "105",
    "Purchase Month": "3",
    "Purchase Date": "16",
    "Purchase Year": "2017",
    "Acquisition": "Y",
    "Acquirer": "Ipsen",
    "Acquisition Price": "952",
    "Acq month": "1",
    "Acq date": "9",
    "Acq year": "2023",
    "Acq notes": ""
  },
  {
    "Company": "Alexion",
    "COUNTRY": "USA",
    "Public/Private": "Public",
    "MarketCap": "41.5 billion",
    "RPDD Month": "12",
    "RPDD Year": "2020",
    "Current Development Stage": "PRV Awarded",
    "PRV Year": "2019",
    "PRV Month": "7",
    "Date": "1",
    "TherapeuticArea1": "Metabolic",
    "TherapeuticArea2": "",
    "Indication": "Lysosomal Acid Lipase deficiency",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Candidate": "KANUMA",
    "Active Ingredient": "Sebelipase alfa",
    "Class1": "Enzyme Replacement",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "Y",
    "Purchased": "N",
    "Purchaser": "NA",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "Y",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Alexion",
    "COUNTRY": "USA",
    "Public/Private": "Public",
    "MarketCap": "41.5 billion",
    "RPDD Month": "12",
    "RPDD Year": "2020",
    "Current Development Stage": "PRV Awarded",
    "PRV Year": "2015",
    "PRV Month": "4",
    "Date": "7",
    "TherapeuticArea1": "Metabolic",
    "TherapeuticArea2": "",
    "Indication": "Hypophosphatasia (HPP)",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Candidate": "STRENSIQ",
    "Active Ingredient": "asfotase alfa",
    "Class1": "Enzyme Replacement",
    "Class2": "",
    "Class3": "",
    "MOA": "recombinant glycoprotein that contains the catalytic domain (the active site) of TNSALP",
    "Redeemed": "",
    "Purchased": "N",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "N",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Alnylym",
    "COUNTRY": "USA",
    "Public/Private": "Public",
    "MarketCap": "31.8 billion",
    "RPDD Month": "12",
    "RPDD Year": "2020",
    "Current Development Stage": "PRV Awarded",
    "PRV Year": "2021",
    "PRV Month": "2",
    "Date": "16",
    "TherapeuticArea1": "Nephrology",
    "TherapeuticArea2": "",
    "Indication": "Primary hyperoxaluria type 1",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Candidate": "OXLUMO",
    "Active Ingredient": "lumasiran",
    "Class1": "RNA interference",
    "Class2": "",
    "Class3": "",
    "MOA": "Silences the HAO1",
    "Redeemed": "",
    "Purchased": "N",
    "Purchaser": "NA",
    "Sale Price (USD Millions)": "NA",
    "Purchase Month": "NA",
    "Purchase Date": "Na",
    "Purchase Year": "NA",
    "Acquisition": "N",
    "Acquirer": "NA",
    "Acquisition Price": "NA",
    "Acq month": "NA",
    "Acq date": "NA",
    "Acq year": "NA",
    "Acq notes": ""
  },
  {
    "Company": "Amryt",
    "COUNTRY": "Ireland",
    "Public/Private": "Public",
    "MarketCap": "500 million",
    "RPDD Month": "12",
    "RPDD Year": "2018",
    "Current Development Stage": "PRV Awarded",
    "PRV Year": "2024",
    "PRV Month": "1",
    "Date": "11",
    "TherapeuticArea1": "Dermatology",
    "TherapeuticArea2": "",
    "Indication": "dystrophic epidermolysis bullosa",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Candidate": "FILSUVEZ",
    "Active Ingredient": "birch triterpenes",
    "Class1": "Gene therapy",
    "Class2": "",
    "Class3": "",
    "MOA": "COL7A1 gene via viral vector",
    "Redeemed": "",
    "Purchased": "N",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "Y",
    "Acquirer": "Chiesi",
    "Acquisition Price": "1,705",
    "Acq month": "1",
    "Acq date": "9",
    "Acq year": "2023",
    "Acq notes": "Under the deal, Chiesi will pay $1.25 billion upfront for Amryt plus up to $225 million more if Amryt's rare skin disease drug Filsuvez can gain an FDA approval and wins a priority review voucher as a result of that nod."
  },
  {
    "Company": "AstraZeneca",
    "COUNTRY": "UK",
    "Public/Private": "Public",
    "MarketCap": "192.3 billion",
    "RPDD Month": "12",
    "RPDD Year": "2016",
    "Current Development Stage": "PRV Awarded",
    "PRV Year": "2020",
    "PRV Month": "9",
    "Date": "16",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Indication": "neurofibromatosis type 1 (NF1-PN)",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Candidate": "KOSELUGO",
    "Active Ingredient": "selumetinib",
    "Class1": "Enzyme inhibitor",
    "Class2": "",
    "Class3": "",
    "MOA": "MEK 1/2 inhibitor",
    "Redeemed": "",
    "Purchased": "N",
    "Purchaser": "NA",
    "Sale Price (USD Millions)": "NA",
    "Purchase Month": "NA",
    "Purchase Date": "Na",
    "Purchase Year": "NA",
    "Acquisition": "Y",
    "Acquirer": "NA",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Biogen",
    "COUNTRY": "USA",
    "Public/Private": "Public",
    "MarketCap": "20.1 billion",
    "RPDD Month": "12",
    "RPDD Year": "2019",
    "Current Development Stage": "PRV Awarded",
    "PRV Year": "2017",
    "PRV Month": "3",
    "Date": "6",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "Spinal muscular atrophy",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Candidate": "SPINRAZA",
    "Active Ingredient": "Gene therapy",
    "Class1": "Gene therapy",
    "Class2": "",
    "Class3": "",
    "MOA": "Antisense oligonucleotides",
    "Redeemed": "",
    "Purchased": "N",
    "Purchaser": "NA",
    "Sale Price (USD Millions)": "NA",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "N",
    "Acquirer": "NA",
    "Acquisition Price": "NA",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "BioMarin",
    "COUNTRY": "USA",
    "Public/Private": "Public",
    "MarketCap": "11.5 billion",
    "RPDD Month": "12",
    "RPDD Year": "2021",
    "Current Development Stage": "PRV Awarded",
    "PRV Year": "2014",
    "PRV Month": "2",
    "Date": "12",
    "TherapeuticArea1": "Metabolic",
    "TherapeuticArea2": "",
    "Indication": "Morquio A syndrome",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Candidate": "VIMIZIM",
    "Active Ingredient": "Elosulfase alfa",
    "Class1": "Enzyme Replacement",
    "Class2": "",
    "Class3": "",
    "MOA": "recombinant chimeric monoclonal antibody to GD2",
    "Redeemed": "",
    "Purchased": "Y",
    "Purchaser": "Undisclosed",
    "Sale Price (USD Millions)": "68",
    "Purchase Month": "7",
    "Purchase Date": "30",
    "Purchase Year": "2014",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "68",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "BioMarin",
    "COUNTRY": "USA",
    "Public/Private": "Public",
    "MarketCap": "11.5 billion",
    "RPDD Month": "12",
    "RPDD Year": "2023",
    "Current Development Stage": "PRV Awarded",
    "PRV Year": "2017",
    "PRV Month": "4",
    "Date": "27",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "Batten disease",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Candidate": "Brineura",
    "Active Ingredient": "cerliponase alfa",
    "Class1": "Enzyme Replacement",
    "Class2": "",
    "Class3": "",
    "MOA": "hydrolytic lysosomal N-terminal tripeptidyl peptidase",
    "Redeemed": "",
    "Purchased": "Y",
    "Purchaser": "Novartis",
    "Sale Price (USD Millions)": "125",
    "Purchase Month": "11",
    "Purchase Date": "21",
    "Purchase Year": "2017",
    "Acquisition": "Y",
    "Acquirer": "NA",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "BioMarin",
    "COUNTRY": "USA",
    "Public/Private": "Public",
    "MarketCap": "11.5 billion",
    "RPDD Month": "12",
    "RPDD Year": "2018",
    "Current Development Stage": "PRV Awarded",
    "PRV Year": "2021",
    "PRV Month": "9",
    "Date": "6",
    "TherapeuticArea1": "Orthopedics",
    "TherapeuticArea2": "",
    "Indication": "Achondroplasia",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Candidate": "Voxzogo",
    "Active Ingredient": "",
    "Class1": "Analogs & derivatives",
    "Class2": "",
    "Class3": "",
    "MOA": "CNP analogs",
    "Redeemed": "",
    "Purchased": "Y",
    "Purchaser": "Undisclosed",
    "Sale Price (USD Millions)": "110",
    "Purchase Month": "2",
    "Purchase Date": "9",
    "Purchase Year": "2022",
    "Acquisition": "Y",
    "Acquirer": "",
    "Acquisition Price": "100",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "bluebird Bio",
    "COUNTRY": "USA",
    "Public/Private": "Public",
    "MarketCap": "500 million",
    "RPDD Month": "12",
    "RPDD Year": "2016",
    "Current Development Stage": "PRV Awarded",
    "PRV Year": "2022",
    "PRV Month": "8",
    "Date": "29",
    "TherapeuticArea1": "Hematology",
    "TherapeuticArea2": "",
    "Indication": "ß-thalassemia",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Candidate": "Zynteglo",
    "Active Ingredient": "betibeglogene autotemcel",
    "Class1": "Gene therapy",
    "Class2": "",
    "Class3": "",
    "MOA": "Gene addition",
    "Redeemed": "",
    "Purchased": "Y",
    "Purchaser": "Bristol Myers Squibb",
    "Sale Price (USD Millions)": "95",
    "Purchase Month": "1",
    "Purchase Date": "5",
    "Purchase Year": "2023",
    "Acquisition": "N",
    "Acquirer": "NA",
    "Acquisition Price": "NA",
    "Acq month": "NA",
    "Acq date": "NA",
    "Acq year": "NA",
    "Acq notes": ""
  },
  {
    "Company": "bluebird Bio",
    "COUNTRY": "USA",
    "Public/Private": "Public",
    "MarketCap": "500 million",
    "RPDD Month": "12",
    "RPDD Year": "2019",
    "Current Development Stage": "PRV Awarded",
    "PRV Year": "2022",
    "PRV Month": "10",
    "Date": "7",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "Cerebral adrenoleukodystrophy",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Candidate": "SKYSONA",
    "Active Ingredient": "elivaldogene autotemcel",
    "Class1": "Gene therapy",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "Y",
    "Purchaser": "argenX",
    "Sale Price (USD Millions)": "102",
    "Purchase Month": "11",
    "Purchase Date": "30",
    "Purchase Year": "2022",
    "Acquisition": "Y",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Chiesi Farmaceutici S.p.A.",
    "COUNTRY": "Italy",
    "Public/Private": "Private",
    "MarketCap": "Not Available",
    "RPDD Month": "12",
    "RPDD Year": "2018",
    "Current Development Stage": "PRV Awarded",
    "PRV Year": "2023",
    "PRV Month": "3",
    "Date": "16",
    "TherapeuticArea1": "Metabolic",
    "TherapeuticArea2": "",
    "Indication": "non-central nervous system manifestations of alpha-mannosidosis",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Candidate": "LAMZEDE",
    "Active Ingredient": "velmanase alfa-tycv",
    "Class1": "Enzyme Replacement",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "N",
    "Purchaser": "NA",
    "Sale Price (USD Millions)": "NA",
    "Purchase Month": "NA",
    "Purchase Date": "Na",
    "Purchase Year": "NA",
    "Acquisition": "N",
    "Acquirer": "NA",
    "Acquisition Price": "NA",
    "Acq month": "NA",
    "Acq date": "Na",
    "Acq year": "NA",
    "Acq notes": ""
  },
  {
    "Company": "Day One",
    "COUNTRY": "USA",
    "Public/Private": "Public",
    "MarketCap": "1.5 billion",
    "RPDD Month": "12",
    "RPDD Year": "2016",
    "Current Development Stage": "PRV Awarded",
    "PRV Year": "2024",
    "PRV Month": "4",
    "Date": "23",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Indication": "Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Candidate": "OJEMDA",
    "Active Ingredient": "Tovorafenib",
    "Class1": "Enzyme inhibitor",
    "Class2": "",
    "Class3": "",
    "MOA": "kinase inhibitors",
    "Redeemed": "",
    "Purchased": "Y",
    "Purchaser": "Undisclosed",
    "Sale Price (USD Millions)": "108",
    "Purchase Month": "5",
    "Purchase Date": "30",
    "Purchase Year": "2024",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Eiger",
    "COUNTRY": "USA",
    "Public/Private": "Public",
    "MarketCap": "200 million",
    "RPDD Month": "12",
    "RPDD Year": "2019",
    "Current Development Stage": "PRV Awarded",
    "PRV Year": "2020",
    "PRV Month": "12",
    "Date": "17",
    "TherapeuticArea1": "Metabolic",
    "TherapeuticArea2": "",
    "Indication": "Hutchinson-Gilford Progeria Syndrome (HGPS)",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Candidate": "ZOKINVY",
    "Active Ingredient": "lonafarnib",
    "Class1": "Enzyme inhibitor",
    "Class2": "",
    "Class3": "",
    "MOA": "Protein farnesyltransferase inhibitor",
    "Redeemed": "",
    "Purchased": "Y",
    "Purchaser": "AbbVie",
    "Sale Price (USD Millions)": "95",
    "Purchase Month": "11",
    "Purchase Date": "23",
    "Purchase Year": "2020",
    "Acquisition": "Y",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "Progeria Research Foundation receives 50% under Collaboration Agreement"
  },
  {
    "Company": "Enzyvant",
    "COUNTRY": "USA",
    "Public/Private": "Private",
    "MarketCap": "Not Available",
    "RPDD Month": "12",
    "RPDD Year": "2021",
    "Current Development Stage": "PRV Awarded",
    "PRV Year": "2021",
    "PRV Month": "10",
    "Date": "27",
    "TherapeuticArea1": "Immunology",
    "TherapeuticArea2": "",
    "Indication": "Congenital athymia",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Candidate": "RETHYMIC",
    "Active Ingredient": "allogeneic processed thymus tissue-agdc",
    "Class1": "Biologic",
    "Class2": "",
    "Class3": "",
    "MOA": "Allogeneic thymus tissue therapy",
    "Redeemed": "",
    "Purchased": "N",
    "Purchaser": "NA",
    "Sale Price (USD Millions)": "NA",
    "Purchase Month": "NA",
    "Purchase Date": "Na",
    "Purchase Year": "NA",
    "Acquisition": "Y",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Genentech",
    "COUNTRY": "USA",
    "Public/Private": "Private",
    "MarketCap": "Subsidiary of Roche",
    "RPDD Month": "12",
    "RPDD Year": "2023",
    "Current Development Stage": "PRV Awarded",
    "PRV Year": "2020",
    "PRV Month": "8",
    "Date": "25",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "Spinal muscular atrophy",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Candidate": "EVRYSDI",
    "Active Ingredient": "risdiplam",
    "Class1": "Gene therapy",
    "Class2": "",
    "Class3": "",
    "MOA": "RNA splicing modifier",
    "Redeemed": "",
    "Purchased": "N",
    "Purchaser": "NA",
    "Sale Price (USD Millions)": "NA",
    "Purchase Month": "NA",
    "Purchase Date": "Na",
    "Purchase Year": "NA",
    "Acquisition": "N",
    "Acquirer": "NA",
    "Acquisition Price": "NA",
    "Acq month": "NA",
    "Acq date": "Na",
    "Acq year": "NA",
    "Acq notes": ""
  },
  {
    "Company": "GW Research",
    "COUNTRY": "UK",
    "Public/Private": "Private",
    "MarketCap": "Subsidiary of Jazz Pharma",
    "RPDD Month": "12",
    "RPDD Year": "2020",
    "Current Development Stage": "PRV Awarded",
    "PRV Year": "2018",
    "PRV Month": "7",
    "Date": "19",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "Lennox-Gastaut Syndrome",
    "Approved Drug": "Y",
    "FDA-Approved Therapy Prior to 2012": "Felbatol; Onfi; Lamictal; Topamax; Banzel",
    "Candidate": "EPIDIOLEX",
    "Active Ingredient": "cannabidiol",
    "Class1": "Organic Chemicals",
    "Class2": "",
    "Class3": "",
    "MOA": "cannabidiol",
    "Redeemed": "",
    "Purchased": "Y",
    "Purchaser": "Biohaven",
    "Sale Price (USD Millions)": "105",
    "Purchase Month": "3",
    "Purchase Date": "19",
    "Purchase Year": "2019",
    "Acquisition": "N",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Ipsen Bio",
    "COUNTRY": "France",
    "Public/Private": "Public",
    "MarketCap": "10 billion",
    "RPDD Month": "12",
    "RPDD Year": "2020",
    "Current Development Stage": "PRV Awarded",
    "PRV Year": "2023",
    "PRV Month": "9",
    "Date": "7",
    "TherapeuticArea1": "Orthopedics",
    "TherapeuticArea2": "",
    "Indication": "Fibrodysplasia Ossificans Progressiva",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Candidate": "SOHONOS",
    "Active Ingredient": "palovarotene",
    "Class1": "Hypoglycemic Agents",
    "Class2": "",
    "Class3": "",
    "MOA": "Retinoic acid receptor gamma agonist",
    "Redeemed": "",
    "Purchased": "Y",
    "Purchaser": "Undisclosed",
    "Sale Price (USD Millions)": "158",
    "Purchase Month": "8",
    "Purchase Date": "27",
    "Purchase Year": "2024",
    "Acquisition": "Y",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Italfarmaco S.p.A.",
    "COUNTRY": "Italy",
    "Public/Private": "Private",
    "MarketCap": "Not Available",
    "RPDD Month": "12",
    "RPDD Year": "2020",
    "Current Development Stage": "PRV Awarded",
    "PRV Year": "2024",
    "PRV Month": "3",
    "Date": "21",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "Duchenne muscular dystrophy",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Candidate": "DUVYZAT",
    "Active Ingredient": "givinostat",
    "Class1": "Enzyme inhibitor",
    "Class2": "",
    "Class3": "",
    "MOA": "Histone deacetylase inhibitor",
    "Redeemed": "",
    "Purchased": "N",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "Y",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Krystal",
    "COUNTRY": "USA",
    "Public/Private": "Public",
    "MarketCap": "2 billion",
    "RPDD Month": "12",
    "RPDD Year": "2018",
    "Current Development Stage": "PRV Awarded",
    "PRV Year": "2023",
    "PRV Month": "6",
    "Date": "6",
    "TherapeuticArea1": "Dermatology",
    "TherapeuticArea2": "",
    "Indication": "dystrophic epidermolysis bullosa",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Candidate": "VYJUVEK",
    "Active Ingredient": "beremagene geperpavec-svdt",
    "Class1": "Gene therapy",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "Y",
    "Purchaser": "Undisclosed",
    "Sale Price (USD Millions)": "100",
    "Purchase Month": "8",
    "Purchase Date": "21",
    "Purchase Year": "2023",
    "Acquisition": "N",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Leadiant Bioscience",
    "COUNTRY": "USA",
    "Public/Private": "Private",
    "MarketCap": "Not Available",
    "RPDD Month": "12",
    "RPDD Year": "2016",
    "Current Development Stage": "PRV Awarded",
    "PRV Year": "2018",
    "PRV Month": "10",
    "Date": "25",
    "TherapeuticArea1": "Immunology",
    "TherapeuticArea2": "",
    "Indication": "Adenosine deaminase deficiency-SCID",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Candidate": "REVCOVI",
    "Active Ingredient": "elapegademase-lvlr",
    "Class1": "Enzyme Replacement",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "N",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Marathon",
    "COUNTRY": "USA",
    "Public/Private": "Private",
    "MarketCap": "Not Available",
    "RPDD Month": "12",
    "RPDD Year": "2019",
    "Current Development Stage": "PRV Awarded",
    "PRV Year": "2017",
    "PRV Month": "2",
    "Date": "10",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "Duchenne muscular dystrophy",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Candidate": "EMFLAZA",
    "Active Ingredient": "deflazacort",
    "Class1": "Immunosuppresant",
    "Class2": "",
    "Class3": "",
    "MOA": "Anti-infllamatory corticosteroid",
    "Redeemed": "",
    "Purchased": "N",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "Y",
    "Acquirer": "PTC",
    "Acquisition Price": "190",
    "Acq month": "3",
    "Acq date": "16",
    "Acq year": "2017",
    "Acq notes": "Sold off Emflaza"
  },
  {
    "Company": "Marinus",
    "COUNTRY": "USA",
    "Public/Private": "Public",
    "MarketCap": "150 million",
    "RPDD Month": "12",
    "RPDD Year": "2021",
    "Current Development Stage": "PRV Awarded",
    "PRV Year": "2022",
    "PRV Month": "9",
    "Date": "7",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "cyclin-dependent kinase-like 5 (CDKL5)",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Candidate": "ZTALMY",
    "Active Ingredient": "ganaxolone",
    "Class1": "Enzyme inhibitor",
    "Class2": "",
    "Class3": "",
    "MOA": "GABA receptor modulator",
    "Redeemed": "",
    "Purchased": "Y",
    "Purchaser": "Novo Nordisk",
    "Sale Price (USD Millions)": "110",
    "Purchase Month": "7",
    "Purchase Date": "14",
    "Purchase Year": "2022",
    "Acquisition": "Y",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Mirum",
    "COUNTRY": "USA",
    "Public/Private": "Public",
    "MarketCap": "1.2 billion",
    "RPDD Month": "12",
    "RPDD Year": "2023",
    "Current Development Stage": "PRV Awarded",
    "PRV Year": "2024",
    "PRV Month": "8",
    "Date": "28",
    "TherapeuticArea1": "Gastroenterology",
    "TherapeuticArea2": "",
    "Indication": "Alagille syndrome (ALGS)",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Candidate": "LIVMARLI",
    "Active Ingredient": "maralixibat",
    "Class1": "Biologic",
    "Class2": "",
    "Class3": "",
    "MOA": "Ileal bile acid transporter (IBAT) inhibitor",
    "Redeemed": "",
    "Purchased": "Y",
    "Purchaser": "Undisclosed",
    "Sale Price (USD Millions)": "110",
    "Purchase Month": "11",
    "Purchase Date": "17",
    "Purchase Year": "2021",
    "Acquisition": "Y",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Neurocrine",
    "COUNTRY": "USA",
    "Public/Private": "Public",
    "MarketCap": "11 billion",
    "RPDD Month": "12",
    "RPDD Year": "2020",
    "Current Development Stage": "PRV Awarded",
    "PRV Year": "2024",
    "PRV Month": "12",
    "Date": "13",
    "TherapeuticArea1": "Endocrinology",
    "TherapeuticArea2": "",
    "Indication": "Congenital Adrenal Hyperplasia",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Candidate": "Crenessity",
    "Active Ingredient": "crinecerfont",
    "Class1": "Pharmacotherapies",
    "Class2": "",
    "Class3": "",
    "MOA": "CRF receptor type 1 and 2 antagonist",
    "Redeemed": "",
    "Purchased": "N",
    "Purchaser": "NA",
    "Sale Price (USD Millions)": "NA",
    "Purchase Month": "NA",
    "Purchase Date": "Na",
    "Purchase Year": "NA",
    "Acquisition": "Y",
    "Acquirer": "NA",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Novartis",
    "COUNTRY": "Switzerland",
    "Public/Private": "Public",
    "MarketCap": "225 billion",
    "RPDD Month": "12",
    "RPDD Year": "2020",
    "Current Development Stage": "PRV Awarded",
    "PRV Year": "2019",
    "PRV Month": "6",
    "Date": "24",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "Spinal muscular atrophy",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Candidate": "ZOLGENSMA",
    "Active Ingredient": "onasemnogene abeparvovec-xioi",
    "Class1": "Gene therapy",
    "Class2": "",
    "Class3": "",
    "MOA": "Gene correction",
    "Redeemed": "",
    "Purchased": "N",
    "Purchaser": "NA",
    "Sale Price (USD Millions)": "NA",
    "Purchase Month": "NA",
    "Purchase Date": "NA",
    "Purchase Year": "NA",
    "Acquisition": "N",
    "Acquirer": "NA",
    "Acquisition Price": "NA",
    "Acq month": "NA",
    "Acq date": "NA",
    "Acq year": "NA",
    "Acq notes": ""
  },
  {
    "Company": "Novartis",
    "COUNTRY": "Switzerland",
    "Public/Private": "Public",
    "MarketCap": "225 billion",
    "RPDD Month": "12",
    "RPDD Year": "2018",
    "Current Development Stage": "PRV Awarded",
    "PRV Year": "2017",
    "PRV Month": "9",
    "Date": "11",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Indication": "Acute lymphoblastic leukemia",
    "Approved Drug": "Y",
    "FDA-Approved Therapy Prior to 2012": "Arranon; Clolar",
    "Candidate": "Kymriah",
    "Active Ingredient": "tisagenlecleucel",
    "Class1": "Immunotherapy",
    "Class2": "",
    "Class3": "",
    "MOA": "CAR T",
    "Redeemed": "",
    "Purchased": "N",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "N",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Novimmune",
    "COUNTRY": "Switzerland",
    "Public/Private": "Private",
    "MarketCap": "Not Available",
    "RPDD Month": "12",
    "RPDD Year": "2016",
    "Current Development Stage": "PRV Awarded",
    "PRV Year": "2018",
    "PRV Month": "12",
    "Date": "13",
    "TherapeuticArea1": "Hematology",
    "TherapeuticArea2": "",
    "Indication": "Hemophagocytic lymphohistiocytosis",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Candidate": "Gamifant",
    "Active Ingredient": "Emapalumab",
    "Class1": "Immunosuppresant",
    "Class2": "",
    "Class3": "",
    "MOA": "Interferon gamma blocking antibody",
    "Redeemed": "",
    "Purchased": "Y",
    "Purchaser": "AstraZeneca",
    "Sale Price (USD Millions)": "95",
    "Purchase Month": "8",
    "Purchase Date": "22",
    "Purchase Year": "2019",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "NS Pharma",
    "COUNTRY": "Japan",
    "Public/Private": "Private",
    "MarketCap": "Not Available",
    "RPDD Month": "12",
    "RPDD Year": "2019",
    "Current Development Stage": "PRV Awarded",
    "PRV Year": "2020",
    "PRV Month": "9",
    "Date": "4",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "Duchenne muscular dystrophy",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Candidate": "VILTEPSO",
    "Active Ingredient": "viltolarsen",
    "Class1": "Gene therapy",
    "Class2": "",
    "Class3": "",
    "MOA": "Antisense oligonucleotides",
    "Redeemed": "",
    "Purchased": "N",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "Y",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Orchard",
    "COUNTRY": "UK",
    "Public/Private": "Public",
    "MarketCap": "800 million",
    "RPDD Month": "12",
    "RPDD Year": "2021",
    "Current Development Stage": "PRV Awarded",
    "PRV Year": "2024",
    "PRV Month": "3",
    "Date": "20",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "Metachromatic leukodystrophy(MLD)",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Candidate": "LENMELDY",
    "Active Ingredient": "atidarsagene autotemcel",
    "Class1": "Gene therapy",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "N",
    "Purchaser": "NA",
    "Sale Price (USD Millions)": "NA",
    "Purchase Month": "NA",
    "Purchase Date": "Na",
    "Purchase Year": "NA",
    "Acquisition": "Y",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Origin",
    "COUNTRY": "USA",
    "Public/Private": "Private",
    "MarketCap": "Not Available",
    "RPDD Month": "12",
    "RPDD Year": "2023",
    "Current Development Stage": "PRV Awarded",
    "PRV Year": "2021",
    "PRV Month": "3",
    "Date": "12",
    "TherapeuticArea1": "Metabolic",
    "TherapeuticArea2": "",
    "Indication": "Molybdenum Cofactor Deficiency Type A",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Candidate": "NULIBRY",
    "Active Ingredient": "fosdenopterin",
    "Class1": "Enzyme Replacement",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "Y",
    "Purchaser": "Undisclosed",
    "Sale Price (USD Millions)": "110",
    "Purchase Month": "5",
    "Purchase Date": "13",
    "Purchase Year": "2022",
    "Acquisition": "N",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Pharming",
    "COUNTRY": "Netherlands",
    "Public/Private": "Public",
    "MarketCap": "1 billion",
    "RPDD Month": "12",
    "RPDD Year": "2020",
    "Current Development Stage": "PRV Awarded",
    "PRV Year": "2023",
    "PRV Month": "3",
    "Date": "24",
    "TherapeuticArea1": "Immunology",
    "TherapeuticArea2": "",
    "Indication": "Activated Phosphoinositide 3-Kinase Delta Syndrome (APDS)",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Candidate": "JOENJA",
    "Active Ingredient": "leniolisib",
    "Class1": "Enzyme inhibitor",
    "Class2": "",
    "Class3": "",
    "MOA": "PI3K-delta inhibitor",
    "Redeemed": "",
    "Purchased": "Y",
    "Purchaser": "Novartis",
    "Sale Price (USD Millions)": "21",
    "Purchase Month": "6",
    "Purchase Date": "1",
    "Purchase Year": "2023",
    "Acquisition": "Y",
    "Acquirer": "Novartis",
    "Acquisition Price": "21",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Prometic",
    "COUNTRY": "Canada",
    "Public/Private": "Private",
    "MarketCap": "Not Available",
    "RPDD Month": "12",
    "RPDD Year": "2021",
    "Current Development Stage": "PRV Awarded",
    "PRV Year": "2021",
    "PRV Month": "7",
    "Date": "2",
    "TherapeuticArea1": "Hematology",
    "TherapeuticArea2": "",
    "Indication": "Hypoplasminogenemia",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Candidate": "RYPLAZIM",
    "Active Ingredient": "plasminogen, human-tvmh",
    "Class1": "Enzyme Replacement",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "Y",
    "Purchaser": "Undisclosed",
    "Sale Price (USD Millions)": "105",
    "Purchase Month": "8",
    "Purchase Date": "9",
    "Purchase Year": "2021",
    "Acquisition": "Y",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "PTC",
    "COUNTRY": "USA",
    "Public/Private": "Public",
    "MarketCap": "3.8 billion",
    "RPDD Month": "12",
    "RPDD Year": "2023",
    "Current Development Stage": "PRV Awarded",
    "PRV Year": "2024",
    "PRV Month": "11",
    "Date": "14",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "aromatic L-amino acid decarboxylase deficiency",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Candidate": "Kebilidi",
    "Active Ingredient": "eladocagene exuparvovec-tneq",
    "Class1": "Gene therapy",
    "Class2": "",
    "Class3": "",
    "MOA": "Anti-infllamatory corticosteroid",
    "Redeemed": "",
    "Purchased": "Y",
    "Purchaser": "Undisclosed",
    "Sale Price (USD Millions)": "150",
    "Purchase Month": "11",
    "Purchase Date": "26",
    "Purchase Year": "2024",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Reata",
    "COUNTRY": "USA",
    "Public/Private": "Public",
    "MarketCap": "2.5 billion",
    "RPDD Month": "12",
    "RPDD Year": "2020",
    "Current Development Stage": "PRV Awarded",
    "PRV Year": "2023",
    "PRV Month": "3",
    "Date": "16",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "Friedreich's ataxia",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Candidate": "SKYCLARYS",
    "Active Ingredient": "omaveloxolone",
    "Class1": "Peptides",
    "Class2": "",
    "Class3": "",
    "MOA": "Nuclear factor erythroid 2-related factor 2 (Nrf2) activator",
    "Redeemed": "",
    "Purchased": "N",
    "Purchaser": "NA",
    "Sale Price (USD Millions)": "NA",
    "Purchase Month": "NA",
    "Purchase Date": "NA",
    "Purchase Year": "NA",
    "Acquisition": "Acquisition",
    "Acquirer": "Biogen",
    "Acquisition Price": "7,300",
    "Acq month": "9",
    "Acq date": "26",
    "Acq year": "2023",
    "Acq notes": ""
  },
  {
    "Company": "Regeneron",
    "COUNTRY": "USA",
    "Public/Private": "Public",
    "MarketCap": "75 billion",
    "RPDD Month": "12",
    "RPDD Year": "2020",
    "Current Development Stage": "PRV Awarded",
    "PRV Year": "2023",
    "PRV Month": "9",
    "Date": "7",
    "TherapeuticArea1": "Immunology",
    "TherapeuticArea2": "",
    "Indication": "CD55-deficient protein-losing enteropathy (PLE) (CHAPLE disease)",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Candidate": "VEOPOZ",
    "Active Ingredient": "pozelimab-bbfg",
    "Class1": "Immunosuppresant",
    "Class2": "",
    "Class3": "",
    "MOA": "TNF-alpha inhibitor",
    "Redeemed": "",
    "Purchased": "N",
    "Purchaser": "NA",
    "Sale Price (USD Millions)": "NA",
    "Purchase Month": "NA",
    "Purchase Date": "Na",
    "Purchase Year": "NA",
    "Acquisition": "Y",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Rhythm",
    "COUNTRY": "USA",
    "Public/Private": "Public",
    "MarketCap": "2.5 billion",
    "RPDD Month": "12",
    "RPDD Year": "2020",
    "Current Development Stage": "PRV Awarded",
    "PRV Year": "2020",
    "PRV Month": "12",
    "Date": "17",
    "TherapeuticArea1": "Endocrinology",
    "TherapeuticArea2": "",
    "Indication": "POMC, PCSK1, and LEPR deficiency",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Candidate": "IMCIVREE",
    "Active Ingredient": "setmelanotide",
    "Class1": "Analogs & derivatives",
    "Class2": "",
    "Class3": "",
    "MOA": "Melanocortin-4 receptor agonist",
    "Redeemed": "",
    "Purchased": "Y",
    "Purchaser": "Alexion",
    "Sale Price (USD Millions)": "100",
    "Purchase Month": "1",
    "Purchase Date": "11",
    "Purchase Year": "2021",
    "Acquisition": "N",
    "Acquirer": "NA",
    "Acquisition Price": "NA",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Sanofi",
    "COUNTRY": "France",
    "Public/Private": "Public",
    "MarketCap": "130 billion",
    "RPDD Month": "12",
    "RPDD Year": "2020",
    "Current Development Stage": "PRV Awarded",
    "PRV Year": "2023",
    "PRV Month": "12",
    "Date": "5",
    "TherapeuticArea1": "Metabolic",
    "TherapeuticArea2": "",
    "Indication": "Acid sphingomyelinase deficiency (ASMD)",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Candidate": "Xenpozyme",
    "Active Ingredient": "olipudase alfa-rpcp",
    "Class1": "Enzyme Replacement",
    "Class2": "",
    "Class3": "",
    "MOA": "Acid sphingomyelinase enzyme replacement",
    "Redeemed": "",
    "Purchased": "N",
    "Purchaser": "NA",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "Y",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Sarepta",
    "COUNTRY": "USA",
    "Public/Private": "Public",
    "MarketCap": "9 billion",
    "RPDD Month": "9",
    "RPDD Day": "21",
    "RPDD Year": "2015",
    "Current Development Stage": "PRV Awarded",
    "PRV Year": "2016",
    "PRV Month": "10",
    "Date": "17",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "Duchenne muscular dystrophy",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Candidate": "EXONDYS 51",
    "Active Ingredient": "eteplirsen",
    "Class1": "Gene therapy",
    "Class2": "",
    "Class3": "",
    "MOA": "Antisense oligonucleotides",
    "Redeemed": "",
    "Purchased": "Y",
    "Purchaser": "Gilead",
    "Sale Price (USD Millions)": "125",
    "Purchase Month": "2",
    "Purchase Date": "21",
    "Purchase Year": "2017",
    "Acquisition": "Y",
    "Acquirer": "Gilead",
    "Acquisition Price": "125",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Sarepta",
    "COUNTRY": "USA",
    "Public/Private": "Public",
    "MarketCap": "9 billion",
    "RPDD Month": "9",
    "RPDD Day": "21",
    "RPDD Year": "2015",
    "Current Development Stage": "Phase 3",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "Limb-Girdle Muscular Dystrophy",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Candidate": "SRP-9003",
    "Active Ingredient": "bidridistrogene xeboparvovec",
    "Class1": "Gene therapy",
    "Class2": "",
    "Class3": "",
    "MOA": "AAVrh74 vector",
    "Redeemed": "",
    "Purchased": "N",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "Y",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Sarepta",
    "COUNTRY": "USA",
    "Public/Private": "Public",
    "MarketCap": "9 billion",
    "RPDD Month": "",
    "RPDD Year": "",
    "Current Development Stage": "PRV Awarded",
    "PRV Year": "2020",
    "PRV Month": "1",
    "Date": "23",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "Duchenne muscular dystrophy",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Candidate": "VYONDYS 53",
    "Active Ingredient": "golodirsen",
    "Class1": "Gene therapy",
    "Class2": "",
    "Class3": "",
    "MOA": "Exon-skipping",
    "Redeemed": "",
    "Purchased": "N",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "Y",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Sarepta",
    "COUNTRY": "USA",
    "Public/Private": "Public",
    "MarketCap": "9 billion",
    "RPDD Month": "",
    "RPDD Year": "",
    "Current Development Stage": "PRV Awarded",
    "PRV Year": "2021",
    "PRV Month": "3",
    "Date": "12",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "Duchenne muscular dystrophy",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Candidate": "AMONDYS 45",
    "Active Ingredient": "casimersen",
    "Class1": "Gene therapy",
    "Class2": "",
    "Class3": "",
    "MOA": "Antisense oligonucleotides",
    "Redeemed": "",
    "Purchased": "N",
    "Purchaser": "N",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "Y",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Sarepta",
    "COUNTRY": "USA",
    "Public/Private": "Public",
    "MarketCap": "9 billion",
    "RPDD Month": "12",
    "RPDD Year": "2020",
    "Current Development Stage": "PRV Awarded",
    "PRV Year": "2023",
    "PRV Month": "7",
    "Date": "17",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "Duchenne muscular dystrophy",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Candidate": "ELEVIDYS",
    "Active Ingredient": "delandistrogene moxeparvovec-rokl",
    "Class1": "Gene therapy",
    "Class2": "",
    "Class3": "",
    "MOA": "AAV",
    "Redeemed": "",
    "Purchased": "Y",
    "Purchaser": "Undisclosed",
    "Sale Price (USD Millions)": "102",
    "Purchase Month": "7",
    "Purchase Date": "5",
    "Purchase Year": "2023",
    "Acquisition": "Y",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Spark",
    "COUNTRY": "USA",
    "Public/Private": "Private",
    "MarketCap": "Subsidiary of Roche",
    "RPDD Month": "12",
    "RPDD Year": "2020",
    "Current Development Stage": "PRV Awarded",
    "PRV Year": "2018",
    "PRV Month": "1",
    "Date": "2",
    "TherapeuticArea1": "Ophthalmology",
    "TherapeuticArea2": "",
    "Indication": "biallelic RPE65 mutation-associated retinal dystrophy",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Candidate": "LUXTURNA",
    "Active Ingredient": "voretigene neparvovec",
    "Class1": "Gene therapy",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "Y",
    "Purchaser": "Jazz",
    "Sale Price (USD Millions)": "110",
    "Purchase Month": "Apr",
    "Purchase Date": "30",
    "Purchase Year": "2018",
    "Acquisition": "Y",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Takeda",
    "COUNTRY": "Japan",
    "Public/Private": "Public",
    "MarketCap": "50 billion",
    "RPDD Month": "12",
    "RPDD Year": "2020",
    "Current Development Stage": "PRV Awarded",
    "PRV Year": "2024",
    "PRV Month": "1",
    "Date": "11",
    "TherapeuticArea1": "Hematology",
    "TherapeuticArea2": "",
    "Indication": "Congenital thrombotic thrombocytopenic purpura (cTTP)",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Candidate": "ADZYNMA",
    "Active Ingredient": "ADAMTS13",
    "Class1": "Enzyme Replacement",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "N",
    "Purchaser": "NA",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "Y",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Travere",
    "COUNTRY": "USA",
    "Public/Private": "Public",
    "MarketCap": "1 billion",
    "RPDD Month": "12",
    "RPDD Year": "2020",
    "Current Development Stage": "PRV Awarded",
    "PRV Year": "2015",
    "PRV Month": "3",
    "Date": "17",
    "TherapeuticArea1": "Gastroenterology",
    "TherapeuticArea2": "",
    "Indication": "Bile acid synthesis disorders",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Candidate": "CHOLBAM",
    "Active Ingredient": "Cholic acid",
    "Class1": "Biologic",
    "Class2": "",
    "Class3": "",
    "MOA": "Cholic acid",
    "Redeemed": "",
    "Purchased": "Y",
    "Purchaser": "Sanofi",
    "Sale Price (USD Millions)": "245",
    "Purchase Month": "5",
    "Purchase Date": "27",
    "Purchase Year": "2015",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Ultragenyx",
    "COUNTRY": "USA",
    "Public/Private": "Public",
    "MarketCap": "4 billion",
    "RPDD Month": "12",
    "RPDD Year": "2020",
    "Current Development Stage": "PRV Awarded",
    "PRV Year": "2018",
    "PRV Month": "8",
    "Date": "15",
    "TherapeuticArea1": "Metabolic",
    "TherapeuticArea2": "",
    "Indication": "X-linked hypophosphatemia(HPP)",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Candidate": "CRYSVITA",
    "Active Ingredient": "burosamab-twza",
    "Class1": "Immunotherapy",
    "Class2": "",
    "Class3": "",
    "MOA": "FGF23-blocking monoclonal antibody",
    "Redeemed": "",
    "Purchased": "N",
    "Purchaser": "NA",
    "Sale Price (USD Millions)": "NA",
    "Purchase Month": "NA",
    "Purchase Date": "NA",
    "Purchase Year": "NA",
    "Acquisition": "N",
    "Acquirer": "NA",
    "Acquisition Price": "NA",
    "Acq month": "NA",
    "Acq date": "NA",
    "Acq year": "NA",
    "Acq notes": ""
  },
  {
    "Company": "Ultragenyx",
    "COUNTRY": "USA",
    "Public/Private": "Public",
    "MarketCap": "4 billion",
    "RPDD Month": "12",
    "RPDD Year": "2020",
    "Current Development Stage": "PRV Awarded",
    "PRV Year": "2017",
    "PRV Month": "11",
    "Date": "15",
    "TherapeuticArea1": "Metabolic",
    "TherapeuticArea2": "",
    "Indication": "Mucopolysaccharidosis Type VII (Sly Syndrome)",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Candidate": "Mepsevii",
    "Active Ingredient": "vestronidase alfa-vjbk",
    "Class1": "Enzyme Replacement",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "Y",
    "Purchaser": "Novartis",
    "Sale Price (USD Millions)": "130",
    "Purchase Month": "12",
    "Purchase Date": "18",
    "Purchase Year": "2017",
    "Acquisition": "N",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "United",
    "COUNTRY": "USA",
    "Public/Private": "Public",
    "MarketCap": "9 billion",
    "RPDD Month": "12",
    "RPDD Year": "2020",
    "Current Development Stage": "PRV Awarded",
    "PRV Year": "2015",
    "PRV Month": "4",
    "Date": "7",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Indication": "neuroblastoma",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Candidate": "UNITUXIN",
    "Active Ingredient": "dinutuximab",
    "Class1": "Immunotherapy",
    "Class2": "",
    "Class3": "",
    "MOA": "GD2-binding monoclonal antibody",
    "Redeemed": "",
    "Purchased": "Y",
    "Purchaser": "AbbVie",
    "Sale Price (USD Millions)": "350",
    "Purchase Month": "11",
    "Purchase Date": "6",
    "Purchase Year": "2015",
    "Acquisition": "Y",
    "Acquirer": "AbbVie",
    "Acquisition Price": "350",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "AbbVie buys last available priority voucher for $350 million"
  },
  {
    "Company": "Vertex",
    "COUNTRY": "USA",
    "Public/Private": "Public",
    "MarketCap": "118 billion",
    "RPDD Month": "12",
    "RPDD Year": "2018",
    "Current Development Stage": "PRV Awarded",
    "PRV Year": "2024",
    "PRV Month": "1",
    "Date": "9",
    "TherapeuticArea1": "Hematology",
    "TherapeuticArea2": "",
    "Indication": "Sickle Cell Disease (SCD)",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Candidate": "CASGEVY",
    "Active Ingredient": "exagamglogene autotemcel",
    "Class1": "Gene therapy",
    "Class2": "",
    "Class3": "",
    "MOA": "Gene editing",
    "Redeemed": "",
    "Purchased": "N",
    "Purchaser": "NA",
    "Sale Price (USD Millions)": "NA",
    "Purchase Month": "NA",
    "Purchase Date": "Na",
    "Purchase Year": "NA",
    "Acquisition": "N",
    "Acquirer": "NA",
    "Acquisition Price": "NA",
    "Acq month": "NA",
    "Acq date": "NA",
    "Acq year": "NA",
    "Acq notes": ""
  },
  {
    "Company": "Vertex",
    "COUNTRY": "USA",
    "Public/Private": "Public",
    "MarketCap": "118 billion",
    "RPDD Month": "12",
    "RPDD Year": "2016",
    "Current Development Stage": "PRV Awarded",
    "PRV Year": "2019",
    "PRV Month": "3",
    "Date": "29",
    "TherapeuticArea1": "Pulmonology",
    "TherapeuticArea2": "",
    "Indication": "Cystic fibrosis",
    "Approved Drug": "Y",
    "FDA-Approved Therapy Prior to 2012": "TOBI; Cayston; Pulomzyme",
    "Candidate": "SYMDEKO",
    "Active Ingredient": "tezacaftor/ivacaftor",
    "Class1": "CFTR modulators",
    "Class2": "",
    "Class3": "",
    "MOA": "Cystic fibrosis transmembrane conductance regulator",
    "Redeemed": "",
    "Purchased": "N",
    "Purchaser": "NA",
    "Sale Price (USD Millions)": "NA",
    "Purchase Month": "NA",
    "Purchase Date": "Na",
    "Purchase Year": "NA",
    "Acquisition": "Y",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Vertex",
    "COUNTRY": "USA",
    "Public/Private": "Public",
    "MarketCap": "118 billion",
    "RPDD Month": "12",
    "RPDD Year": "2019",
    "Current Development Stage": "PRV Awarded",
    "PRV Year": "2020",
    "PRV Month": "9",
    "Date": "15",
    "TherapeuticArea1": "Pulmonology",
    "TherapeuticArea2": "",
    "Indication": "Cystic fibrosis",
    "Approved Drug": "Y",
    "FDA-Approved Therapy Prior to 2012": "TOBI; Cayston; Pulomzyme",
    "Candidate": "TRIKAFTA",
    "Active Ingredient": "elexacaftor/tezacaftor/ivacaftor",
    "Class1": "Enzyme inhibitor",
    "Class2": "",
    "Class3": "",
    "MOA": "CFTR modulators",
    "Redeemed": "",
    "Purchased": "N",
    "Purchaser": "NA",
    "Sale Price (USD Millions)": "NA",
    "Purchase Month": "NA",
    "Purchase Date": "Na",
    "Purchase Year": "NA",
    "Acquisition": "Y",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Wellstat",
    "COUNTRY": "USA",
    "Public/Private": "Private",
    "MarketCap": "Not Available",
    "RPDD Month": "12",
    "RPDD Year": "2021",
    "Current Development Stage": "PRV Awarded",
    "PRV Year": "2015",
    "PRV Month": "4",
    "Date": "7",
    "TherapeuticArea1": "Metabolic",
    "TherapeuticArea2": "",
    "Indication": "Hereditary orotic aciduria",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Candidate": "Xuriden",
    "Active Ingredient": "uridine triacetate",
    "Class1": "Analogs & derivatives",
    "Class2": "",
    "Class3": "",
    "MOA": "Pyrimidine analogs",
    "Redeemed": "",
    "Purchased": "Y",
    "Purchaser": "AstraZeneca",
    "Sale Price (USD Millions)": "Undisclosed",
    "Purchase Month": "9",
    "Purchase Date": "9",
    "Purchase Year": "2015",
    "Acquisition": "N",
    "Acquirer": "",
  "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "X4",
    "COUNTRY": "USA",
    "Public/Private": "Public",
    "MarketCap": "300 million",
    "RPDD Month": "12",
    "RPDD Year": "2023",
    "Current Development Stage": "PRV Awarded",
    "PRV Year": "2024",
    "PRV Month": "5",
    "Date": "16",
    "TherapeuticArea1": "Immunology",
    "TherapeuticArea2": "",
    "Indication": "WHIM Syndrome",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Candidate": "Xolremdi",
    "Active Ingredient": "mavorixafor",
    "Class1": "Pharmacotherapies",
    "Class2": "",
    "Class3": "",
    "MOA": "CXC chemokine receptor 4 antagonist",
    "Redeemed": "",
    "Purchased": "Y",
    "Purchaser": "Undisclosed",
    "Sale Price (USD Millions)": "105",
    "Purchase Month": "5",
    "Purchase Date": "9",
    "Purchase Year": "2024",
    "Acquisition": "N",
    "Acquirer": "NA",
    "Acquisition Price": "NA",
    "Acq month": "NA",
    "Acq date": "NA",
    "Acq year": "NA",
    "Acq notes": ""
  },
  {
    "Company": "Y-mAbs",
    "COUNTRY": "USA",
    "Public/Private": "Public",
    "MarketCap": "700 million",
    "RPDD Month": "12",
    "RPDD Year": "2020",
    "Current Development Stage": "PRV Awarded",
    "PRV Year": "2020",
    "PRV Month": "12",
    "Date": "7",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Indication": "neuroblastoma",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Candidate": "DANYELZA",
    "Active Ingredient": "",
    "Class1": "Immunotherapy",
    "Class2": "",
    "Class3": "",
    "MOA": "Monoclonal antibody (anti-GD2)",
    "Redeemed": "",
    "Purchased": "Y",
    "Purchaser": "United",
    "Sale Price (USD Millions)": "105",
    "Purchase Month": "12",
    "Purchase Date": "28",
    "Purchase Year": "2020",
    "Acquisition": "Y",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Aardvark",
    "COUNTRY": "USA",
    "Public/Private": "Public",
    "MarketCap": "280 million",
    "RPDD Month": "12",
    "RPDD Year": "2020",
    "Current Development Stage": "Phase 2",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Endocrinology",
    "TherapeuticArea2": "Genetic",
    "Indication": "Prader-Willi Syndrome",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Candidate": "ARD-101",
    "Active Ingredient": "",
    "Class1": "Anti-inflammatories",
    "Class2": "Obesity",
    "Class3": "Small molecules",
    "MOA": "G protein-coupled receptor agonists",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Advent",
    "COUNTRY": "USA",
    "Public/Private": "Private",
    "MarketCap": "Not Available",
    "RPDD Month": "7",
    "RPDD Year": "2023",
    "Current Development Stage": "Preclinical",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Pulmonology",
    "TherapeuticArea2": "Neonatology",
    "Indication": "Bronchopulmonary Dysplasia",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Candidate": "Vitamin A palmitate",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Alnylym",
    "COUNTRY": "USA",
    "Public/Private": "Public",
    "MarketCap": "31.8 billion",
    "RPDD Month": "8",
    "RPDD Year": "2022",
    "Current Development Stage": "Phase 2",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Endocrinology",
    "TherapeuticArea2": "Genetic",
    "Indication": "Prader-Willi Syndrome",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Candidate": "ARD-101",
    "Active Ingredient": "",
    "Class1": "Anti-inflammatories",
    "Class2": "Obesity",
    "Class3": "Small molecules",
    "MOA": "G protein-coupled receptor agonists",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Amryt",
    "COUNTRY": "Ireland",
    "Public/Private": "Public",
    "MarketCap": "500 million",
    "RPDD Month": "7",
    "RPDD Year": "2022",
    "Current Development Stage": "Preclinical",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Pulmonology",
    "TherapeuticArea2": "Neonatology",
    "Indication": "Bronchopulmonary Dysplasia",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Candidate": "Vitamin A palmitate",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Arcturus",
    "COUNTRY": "USA",
    "Public/Private": "Public",
    "MarketCap": "480 million",
    "RPDD Month": "11",
    "RPDD Year": "2023",
    "Current Development Stage": "Phase 1b",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Pulmonology",
    "TherapeuticArea2": "Genetic",
    "Indication": "Cystic Fibrosis",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Candidate": "ARCT-032",
    "Active Ingredient": "",
    "Class1": "Antifibrotics",
    "Class2": "RNA",
    "Class3": "",
    "MOA": "Cystic fibrosis transmembrane conductance regulator expression stimulants",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Arcturus",
    "COUNTRY": "USA",
    "Public/Private": "Public",
    "MarketCap": "480 million",
    "RPDD Month": "11",
    "RPDD Year": "2023",
    "Current Development Stage": "Phase 1b",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Metabolic",
    "TherapeuticArea2": "",
    "Indication": "Ornithine Transcarbamylase Deficiency",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Candidate": "ARCT-810",
    "Active Ingredient": "",
    "Class1": "RNA",
    "Class2": "",
    "Class3": "",
    "MOA": "Ornithine carbamoyltransferase expression stimulants",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "AstraZeneca",
    "COUNTRY": "UK",
    "Public/Private": "Public",
    "MarketCap": "192.3 billion",
    "RPDD Month": "11",
    "RPDD Year": "2022",
    "Current Development Stage": "Phase 1b",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Pulmonology",
    "TherapeuticArea2": "Genetic",
    "Indication": "Cystic Fibrosis",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Candidate": "ARCT-032",
    "Active Ingredient": "",
    "Class1": "Antifibrotics",
    "Class2": "RNA",
    "Class3": "",
    "MOA": "Cystic fibrosis transmembrane conductance regulator expression stimulants",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "AUM",
    "COUNTRY": "USA",
    "Public/Private": "Public",
    "MarketCap": "45 million",
    "RPDD Month": "1",
    "RPDD Year": "2023",
    "Current Development Stage": "Preclinical",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Indication": "Neuroblastoma",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Candidate": "AUM302",
    "Active Ingredient": "",
    "Class1": "2 ring heterocyclic compounds",
    "Class2": "Antineoplastics",
    "Class3": "Aza compounds",
    "MOA": "1 Phosphatidylinositol 3 kinase inhibitors; MTOR protein inhibitors; PIM3 protein inhibitors; Proto oncogene protein c pim 1 inhibitors; Proto-oncogene protein pim-2 inhibitors",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Biogen",
    "COUNTRY": "USA",
    "Public/Private": "Public",
    "MarketCap": "20.1 billion",
    "RPDD Month": "11",
    "RPDD Year": "2022",
    "Current Development Stage": "Phase 1b",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Metabolic",
    "TherapeuticArea2": "",
    "Indication": "Ornithine Transcarbamylase Deficiency",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Candidate": "ARCT-810",
    "Active Ingredient": "",
    "Class1": "RNA",
    "Class2": "",
    "Class3": "",
    "MOA": "Ornithine carbamoyltransferase expression stimulants",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "BioMarin",
    "COUNTRY": "USA",
    "Public/Private": "Public",
    "MarketCap": "11.5 billion",
    "RPDD Month": "1",
    "RPDD Year": "2022",
    "Current Development Stage": "Preclinical",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Indication": "Neuroblastoma",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Candidate": "AUM302",
    "Active Ingredient": "",
    "Class1": "2 ring heterocyclic compounds",
    "Class2": "Antineoplastics",
    "Class3": "Aza compounds",
    "MOA": "1 Phosphatidylinositol 3 kinase inhibitors; MTOR protein inhibitors; PIM3 protein inhibitors; Proto oncogene protein c pim 1 inhibitors; Proto-oncogene protein pim-2 inhibitors",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "BioMarin",
    "COUNTRY": "USA",
    "Public/Private": "Public",
    "MarketCap": "11.5 billion",
    "RPDD Month": "8",
    "RPDD Year": "2022",
    "Current Development Stage": "Phase 1",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "Dravet Syndrome",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Candidate": "BL-001",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "BioMarin",
    "COUNTRY": "USA",
    "Public/Private": "Public",
    "MarketCap": "11.5 billion",
    "RPDD Month": "8",
    "RPDD Year": "2022",
    "Current Development Stage": "Preclinical",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "Dopamine Transporter Deficiency Syndrome",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Candidate": "BGT-DTDS",
    "Active Ingredient": "",
    "Class1": "AAV",
    "Class2": "AAV2",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Bloom Science",
    "COUNTRY": "USA",
    "Public/Private": "Private",
    "MarketCap": "Not Available",
    "RPDD Month": "8",
    "RPDD Year": "2023",
    "Current Development Stage": "Phase 1",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "Dravet Syndrome",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Candidate": "BL-001",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Bloomsbury Genetic",
    "COUNTRY": "UK",
    "Public/Private": "Private",
    "MarketCap": "Not Available",
    "RPDD Month": "8",
    "RPDD Year": "2023",
    "Current Development Stage": "Preclinical",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "Dopamine Transporter Deficiency Syndrome",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Candidate": "BGT-DTDS",
    "Active Ingredient": "",
    "Class1": "AAV",
    "Class2": "AAV2",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Bloomsbury Genetic",
    "COUNTRY": "UK",
    "Public/Private": "Private",
    "MarketCap": "Not Available",
    "RPDD Month": "8",
    "RPDD Year": "2023",
    "Current Development Stage": "Phase 1/2",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "Ornithine Transcarbamylase Deficiency",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Candidate": "BGT-OTCD",
    "Active Ingredient": "",
    "Class1": "AAV",
    "Class2": "AAV2",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Bloomsbury Genetic",
    "COUNTRY": "UK",
    "Public/Private": "Private",
    "MarketCap": "Not Available",
    "RPDD Month": "8",
    "RPDD Year": "2023",
    "Current Development Stage": "Preclinical",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "Infantile Neuroaxonal Dystrophy",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Candidate": "BGT-INAD",
    "Active Ingredient": "",
    "Class1": "AAV",
    "Class2": "AAV2",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Bloomsbury Genetic",
    "COUNTRY": "UK",
    "Public/Private": "Private",
    "MarketCap": "Not Available",
    "RPDD Month": "8",
    "RPDD Year": "2023",
    "Current Development Stage": "Preclinical",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "Metabolic",
    "Indication": "Niemann-Pick Disease Type C",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Candidate": "BGT-NPC",
    "Active Ingredient": "",
    "Class1": "AAV",
    "Class2": "AAV9",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "bluebird Bio",
    "COUNTRY": "USA",
    "Public/Private": "Public",
    "MarketCap": "500 million",
    "RPDD Month": "8",
    "RPDD Year": "2022",
    "Current Development Stage": "Phase 1/2",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "Ornithine Transcarbamylase Deficiency",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Candidate": "BGT-OTCD",
    "Active Ingredient": "",
    "Class1": "AAV",
    "Class2": "AAV2",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "bluebird Bio",
    "COUNTRY": "USA",
    "Public/Private": "Public",
    "MarketCap": "500 million",
    "RPDD Month": "8",
    "RPDD Year": "2022",
    "Current Development Stage": "Preclinical",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "Infantile Neuroaxonal Dystrophy",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Candidate": "BGT-INAD",
    "Active Ingredient": "",
    "Class1": "AAV",
    "Class2": "AAV2",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Chiesi Farmaceutici S.p.A.",
    "COUNTRY": "Italy",
    "Public/Private": "Private",
    "MarketCap": "Not Available",
    "RPDD Month": "8",
    "RPDD Year": "2022",
    "Current Development Stage": "Preclinical",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "Metabolic",
    "Indication": "Niemann-Pick Disease Type C",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Candidate": "BGT-NPC",
    "Active Ingredient": "",
    "Class1": "AAV",
    "Class2": "AAV9",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Daiichi Sankyo",
    "COUNTRY": "Japan",
    "Public/Private": "Public",
    "MarketCap": "45 billion",
    "RPDD Month": "5",
    "RPDD Year": "2023",
    "Current Development Stage": "Phase 1",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Dermatology",
    "TherapeuticArea2": "Genetic",
    "Indication": "Netherton Syndrome",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Candidate": "DS-2325",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Day One",
    "COUNTRY": "USA",
    "Public/Private": "Public",
    "MarketCap": "1.5 billion",
    "RPDD Month": "5",
    "RPDD Year": "2022",
    "Current Development Stage": "Phase 1",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Dermatology",
    "TherapeuticArea2": "Genetic",
    "Indication": "Netherton Syndrome",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Candidate": "DS-2325",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Dyne",
    "COUNTRY": "USA",
    "Public/Private": "Public",
    "MarketCap": "1.4 billion",
    "RPDD Month": "5",
    "RPDD Year": "2023",
    "Current Development Stage": "Phase 1/2",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "Duchenne Muscular Dystrophy",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Candidate": "DYNE-251",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Edgewise",
    "COUNTRY": "USA",
    "Public/Private": "Pubic",
    "MarketCap": "2.5 billion",
    "RPDD Month": "11",
    "RPDD Year": "2023",
    "Current Development Stage": "Phase 2",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "Duchenne Muscular Dystrophy",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Candidate": "EDG-5506",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Eiger",
    "COUNTRY": "USA",
    "Public/Private": "Public",
    "MarketCap": "200 million",
    "RPDD Month": "5",
    "RPDD Year": "2022",
    "Current Development Stage": "Phase 1/2",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "Duchenne Muscular Dystrophy",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Candidate": "DYNE-251",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Elastrin",
    "COUNTRY": "USA",
    "Public/Private": "Private",
    "MarketCap": "Not Available",
    "RPDD Month": "10",
    "RPDD Year": "2023",
    "Current Development Stage": "Preclinical",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Cardiovascular",
    "TherapeuticArea2": "",
    "Indication": "Generalized Arterial Calcification of Infancy",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Candidate": "ELT-001",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Enzyvant",
    "COUNTRY": "USA",
    "Public/Private": "Private",
    "MarketCap": "Not Available",
    "RPDD Month": "11",
    "RPDD Year": "2022",
    "Current Development Stage": "Phase 2",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "Duchenne Muscular Dystrophy",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Candidate": "EDG-5506",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "FLAG",
    "COUNTRY": "USA",
    "Public/Private": "Private",
    "MarketCap": "Not Available",
    "RPDD Month": "2",
    "RPDD Year": "2023",
    "Current Development Stage": "Preclinical",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Indication": "Diffuse Intrinsic Pontine Glioma",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Candidate": "FLAG-003",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "GC",
    "COUNTRY": "Korea",
    "Public/Private": "Pubic",
    "MarketCap": "1 billion",
    "RPDD Month": "1",
    "RPDD Year": "2023",
    "Current Development Stage": "Preclinical",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "Metabolic",
    "Indication": "Sanfilippo Syndrome A",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Candidate": "GC1130A",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Genentech",
    "COUNTRY": "USA",
    "Public/Private": "Private",
    "MarketCap": "Subsidiary of Roche",
    "RPDD Month": "10",
    "RPDD Year": "2022",
    "Current Development Stage": "Preclinical",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Cardiovascular",
    "TherapeuticArea2": "",
    "Indication": "Generalized Arterial Calcification of Infancy",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Candidate": "ELT-001",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Gut-Brain-Axis",
    "COUNTRY": "USA",
    "Public/Private": "Private",
    "MarketCap": "Not Available",
    "RPDD Month": "8",
    "RPDD Year": "2023",
    "Current Development Stage": "Phase 2",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "Genetic",
    "Indication": "Pitt-Hopkins Syndrome",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Candidate": "Microbiota Transplant Therapy",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "GW Research",
    "COUNTRY": "UK",
    "Public/Private": "Private",
    "MarketCap": "Subsidiary of Jazz Pharma",
    "RPDD Month": "2",
    "RPDD Year": "2022",
    "Current Development Stage": "Preclinical",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Indication": "Diffuse Intrinsic Pontine Glioma",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Candidate": "FLAG-003",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "HuidaGene",
    "COUNTRY": "China",
    "Public/Private": "Private",
    "MarketCap": "Not Available",
    "RPDD Month": "12",
    "RPDD Year": "2023",
    "Current Development Stage": "Preclinical",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "Duchenne Muscular Dystrophy",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Candidate": "HG302",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "HuidaGene",
    "COUNTRY": "China",
    "Public/Private": "Private",
    "MarketCap": "Not Available",
    "RPDD Month": "8",
    "RPDD Year": "2023",
    "Current Development Stage": "Preclinical",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "Genetic",
    "Indication": "MECP2 duplication syndrome",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Candidate": "HG204",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "HuidaGene",
    "COUNTRY": "China",
    "Public/Private": "Private",
    "MarketCap": "Not Available",
    "RPDD Month": "8",
    "RPDD Year": "2023",
    "Current Development Stage": "Phase 1",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Ophthalmology",
    "TherapeuticArea2": "Genetic",
    "Indication": "RPE65 mutations inherited retinal disease",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Candidate": "HG004",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Ionis",
    "COUNTRY": "USA",
    "Public/Private": "Public",
    "MarketCap": "4.8 billion",
    "RPDD Month": "10",
    "RPDD Year": "2023",
    "Current Development Stage": "Preclinical",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "Genetic",
    "Indication": "Pelizaeus-Merzbacher Disease",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Candidate": "ION356",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Ipsen Bio",
    "COUNTRY": "France",
    "Public/Private": "Public",
    "MarketCap": "10 billion",
    "RPDD Month": "1",
    "RPDD Year": "2021",
    "Current Development Stage": "Preclinical",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "Metabolic",
    "Indication": "Sanfilippo Syndrome A",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Candidate": "GC1130A",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Italfarmaco S.p.A.",
    "COUNTRY": "Italy",
    "Public/Private": "Private",
    "MarketCap": "Not Available",
    "RPDD Month": "8",
    "RPDD Year": "2021",
    "Current Development Stage": "Phase 2",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "Genetic",
    "Indication": "Pitt-Hopkins Syndrome",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Candidate": "Microbiota Transplant Therapy",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "JCR",
    "COUNTRY": "Japan",
    "Public/Private": "Public",
    "MarketCap": "450 million",
    "RPDD Month": "1",
    "RPDD Year": "2023",
    "Current Development Stage": "Phase 3",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Metabolic",
    "TherapeuticArea2": "",
    "Indication": "Mucopolysaccharidosis Type II",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Candidate": "JR-141",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Krystal",
    "COUNTRY": "USA",
    "Public/Private": "Public",
    "MarketCap": "2 billion",
    "RPDD Month": "12",
    "RPDD Year": "2021",
    "Current Development Stage": "Preclinical",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "Duchenne Muscular Dystrophy",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Candidate": "HG302",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Lactiga US",
    "COUNTRY": "USA",
    "Public/Private": "Private",
    "MarketCap": "Not Available",
    "RPDD Month": "8",
    "RPDD Year": "2023",
    "Current Development Stage": "Preclinical",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Immunology",
    "TherapeuticArea2": "",
    "Indication": "Common Variable Immunodeficiency",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Candidate": "LCTG-001",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Laminar",
    "COUNTRY": "USA",
    "Public/Private": "Private",
    "MarketCap": "Not Available",
    "RPDD Month": "9",
    "RPDD Year": "2023",
    "Current Development Stage": "Phase 1",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Indication": "Pediatric-Type Diffuse High Grade Glioma",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Candidate": "LAM561",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Leadiant Bioscience",
    "COUNTRY": "USA",
    "Public/Private": "Private",
    "MarketCap": "Not Available",
    "RPDD Month": "8",
    "RPDD Year": "2021",
    "Current Development Stage": "Preclinical",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "Genetic",
    "Indication": "MECP2 duplication syndrome",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Candidate": "HG204",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Marathon",
    "COUNTRY": "USA",
    "Public/Private": "Private",
    "MarketCap": "Not Available",
    "RPDD Month": "8",
    "RPDD Year": "2021",
    "Current Development Stage": "Phase 1",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Ophthalmology",
    "TherapeuticArea2": "Genetic",
    "Indication": "RPE65 mutations inherited retinal disease",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Candidate": "HG004",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Marinus",
    "COUNTRY": "USA",
    "Public/Private": "Public",
    "MarketCap": "150 million",
    "RPDD Month": "10",
    "RPDD Year": "2021",
    "Current Development Stage": "Preclinical",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "Genetic",
    "Indication": "Pelizaeus-Merzbacher Disease",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Candidate": "ION356",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Mirum",
    "COUNTRY": "USA",
    "Public/Private": "Public",
    "MarketCap": "1.2 billion",
    "RPDD Month": "1",
    "RPDD Year": "2021",
    "Current Development Stage": "Phase 3",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Metabolic",
    "TherapeuticArea2": "",
    "Indication": "Mucopolysaccharidosis Type II",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Candidate": "JR-141",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Myopax",
    "COUNTRY": "Germany",
    "Public/Private": "Private",
    "MarketCap": "Not Available",
    "RPDD Month": "7",
    "RPDD Year": "2023",
    "Current Development Stage": "Preclinical",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Urology",
    "TherapeuticArea2": "",
    "Indication": "Exstrophy-Epispadias Complex",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Candidate": "Stem Cell Therapy",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Neurocrine",
    "COUNTRY": "USA",
    "Public/Private": "Public",
    "MarketCap": "11 billion",
    "RPDD Month": "8",
    "RPDD Year": "2021",
    "Current Development Stage": "Preclinical",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Immunology",
    "TherapeuticArea2": "",
    "Indication": "Common Variable Immunodeficiency",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Candidate": "LCTG-001",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "NorthSea",
    "COUNTRY": "Netherlands",
    "Public/Private": "Private",
    "MarketCap": "Not Available",
    "RPDD Month": "10",
    "RPDD Year": "2023",
    "Current Development Stage": "Phase 2a",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Gastroenterology",
    "TherapeuticArea2": "Hepatology",
    "Indication": "Intestinal Failure-Associated Liver Disease",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Candidate": "SEFA-6179",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Novartis",
    "COUNTRY": "Switzerland",
    "Public/Private": "Public",
    "MarketCap": "225 billion",
    "RPDD Month": "9",
    "RPDD Year": "2021",
    "Current Development Stage": "Phase 1",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Indication": "Pediatric-Type Diffuse High Grade Glioma",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Candidate": "LAM561",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Novartis",
    "COUNTRY": "Switzerland",
    "Public/Private": "Public",
    "MarketCap": "225 billion",
    "RPDD Month": "7",
    "RPDD Year": "2021",
    "Current Development Stage": "Preclinical",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Urology",
    "TherapeuticArea2": "",
    "Indication": "Exstrophy-Epispadias Complex",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Candidate": "Stem Cell Therapy",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Novimmune",
    "COUNTRY": "Switzerland",
    "Public/Private": "Private",
    "MarketCap": "Not Available",
    "RPDD Month": "10",
    "RPDD Year": "2021",
    "Current Development Stage": "Phase 2a",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Gastroenterology",
    "TherapeuticArea2": "Hepatology",
    "Indication": "Intestinal Failure-Associated Liver Disease",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Candidate": "SEFA-6179",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "NS Pharma",
    "COUNTRY": "Japan",
    "Public/Private": "Private",
    "MarketCap": "Not Available",
    "RPDD Month": "4",
    "RPDD Year": "2021",
    "Current Development Stage": "Phase 1/2",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Ophthalmology",
    "TherapeuticArea2": "Genetic",
    "Indication": "Stargardt Disease",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Candidate": "OCU410ST",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Ocugen",
    "COUNTRY": "USA",
    "Public/Private": "Public",
    "MarketCap": "200 million",
    "RPDD Month": "4",
    "RPDD Year": "2023",
    "Current Development Stage": "Phase 1/2",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Ophthalmology",
    "TherapeuticArea2": "Genetic",
    "Indication": "Stargardt Disease",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Candidate": "OCU410ST",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Orchard",
    "COUNTRY": "UK",
    "Public/Private": "Public",
    "MarketCap": "800 million",
    "RPDD Month": "1",
    "RPDD Year": "2021",
    "Current Development Stage": "Preclinical",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Indication": "Adrenocortical Carcinoma",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Candidate": "OR-449",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Origin",
    "COUNTRY": "USA",
    "Public/Private": "Private",
    "MarketCap": "Not Available",
    "RPDD Month": "8",
    "RPDD Year": "2021",
    "Current Development Stage": "Preclinical",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "Duchenne Muscular Dystrophy",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Candidate": "SAT-3153",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Orphagen",
    "COUNTRY": "USA",
    "Public/Private": "Private",
    "MarketCap": "Not Available",
    "RPDD Month": "1",
    "RPDD Year": "2023",
    "Current Development Stage": "Preclinical",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Indication": "Adrenocortical Carcinoma",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Candidate": "OR-449",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Pharming",
    "COUNTRY": "Netherlands",
    "Public/Private": "Public",
    "MarketCap": "1 billion",
    "RPDD Month": "11",
    "RPDD Year": "2021",
    "Current Development Stage": "Preclinical",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Hematology",
    "TherapeuticArea2": "",
    "Indication": "Hemophilia Type A",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Candidate": "Cell Pouch",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Prometic",
    "COUNTRY": "Canada",
    "Public/Private": "Private",
    "MarketCap": "Not Available",
    "RPDD Month": "5",
    "RPDD Year": "2021",
    "Current Development Stage": "Preclinical",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Hematology",
    "TherapeuticArea2": "Metabolic",
    "Indication": "Osteopetrosis",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Candidate": "SIS-101-ADO",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "PTC",
    "COUNTRY": "USA",
    "Public/Private": "Public",
    "MarketCap": "3.8 billion",
    "RPDD Month": "11",
    "RPDD Year": "2021",
    "Current Development Stage": "Phase 2b",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "Neurology",
    "Indication": "Neurofibromatosis type 1-associated Plexiform Neurofibromas",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Candidate": "mirdametinib",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Reata",
    "COUNTRY": "USA",
    "Public/Private": "Public",
    "MarketCap": "2.5 billion",
    "RPDD Month": "4",
    "RPDD Year": "2021",
    "Current Development Stage": "Phase 1",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Indication": "Ewing's Sarcoma",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Candidate": "TP-1287",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Regeneron",
    "COUNTRY": "USA",
    "Public/Private": "Public",
    "MarketCap": "75 billion",
    "RPDD Month": "2",
    "RPDD Year": "2021",
    "Current Development Stage": "Preclinical",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "TUBB4A Leukodystrophy",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Candidate": "TBD",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Satellos",
    "COUNTRY": "Canada",
    "Public/Private": "Public",
    "MarketCap": "90 million",
    "RPDD Month": "8",
    "RPDD Year": "2023",
    "Current Development Stage": "Preclinical",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "Duchenne Muscular Dystrophy",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Candidate": "SAT-3153",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Sernova",
    "COUNTRY": "Canada",
    "Public/Private": "Public",
    "MarketCap": "50 million",
    "RPDD Month": "11",
    "RPDD Year": "2023",
    "Current Development Stage": "Preclinical",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Hematology",
    "TherapeuticArea2": "",
    "Indication": "Hemophilia Type A",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Candidate": "Cell Pouch",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "SiSaf",
    "COUNTRY": "UK",
    "Public/Private": "Public",
    "MarketCap": "611.48M",
    "RPDD Month": "5",
    "RPDD Year": "2023",
    "Current Development Stage": "Preclinical",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Hematology",
    "TherapeuticArea2": "Metabolic",
    "Indication": "Osteopetrosis",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Candidate": "SIS-101-ADO",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "SpringWorks",
    "COUNTRY": "USA",
    "Public/Private": "Public",
    "MarketCap": "4.5 billioon",
    "RPDD Month": "11",
    "RPDD Year": "2023",
    "Current Development Stage": "Phase 2b",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "Neurology",
    "Indication": "Neurofibromatosis type 1-associated Plexiform Neurofibromas",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Candidate": "mirdametinib",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Sumitomo",
    "COUNTRY": "Japan",
    "Public/Private": "Public",
    "MarketCap": "2 billion",
    "RPDD Month": "4",
    "RPDD Year": "2023",
    "Current Development Stage": "Phase 1",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Indication": "Ewing's Sarcoma",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Candidate": "TP-1287",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "SynaptixBio",
    "COUNTRY": "USA",
    "Public/Private": "Private",
    "MarketCap": "Not Available",
    "RPDD Month": "2",
    "RPDD Year": "2023",
    "Current Development Stage": "Preclinical",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "TUBB4A Leukodystrophy",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Candidate": "TBD",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Synlogic",
    "COUNTRY": "USA",
    "Public/Private": "Public",
    "MarketCap": "16M",
    "RPDD Month": "1",
    "RPDD Year": "2023",
    "Current Development Stage": "Phase 3",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Metabolic",
    "TherapeuticArea2": "",
    "Indication": "Phenylketonuria",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Candidate": "labafenogene marselecobac (SYNB1934)",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Takeda",
    "COUNTRY": "Japan",
    "Public/Private": "Public",
    "MarketCap": "50 billion",
    "RPDD Month": "8",
    "RPDD Year": "2023",
    "Current Development Stage": "Phase 3",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Hematology",
    "TherapeuticArea2": "",
    "Indication": "Congenital Thrombotic Thrombocytopenic Purpura",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Candidate": "ADZYNMA",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "Tetra (Shionogi)",
    "COUNTRY": "Japan",
    "Public/Private": "Public",
    "MarketCap": "12 billion",
    "RPDD Month": "9",
    "RPDD Year": "2023",
    "Current Development Stage": "Preclinical",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "Genetic",
    "Indication": "Fragile X Syndrome",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Candidate": "zatolmilast",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  },
  {
    "Company": "AlveoGene",
    "COUNTRY": "UK",
    "Public/Private": "Private",
    "MarketCap": "Not Available",
    "RPDD Month": "11",
    "RPDD Year": "2024",
    "Current Development Stage": "Preclinical",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Pulmonology",
    "TherapeuticArea2": "Genetic",
    "Indication": "Lethal Neonatal Surfactant Protein B (SP-B) Deficiency",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Candidate": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": ""
  }
]